UK Markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.03-0.44 (-5.89%)
As of 03:10PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.47
Open7.38
Bid7.04 x 1000
Ask7.06 x 800
Day's range7.02 - 7.41
52-week range6.90 - 50.09
Volume380,529
Avg. volume332,368
Market cap1.315B
Beta (5Y monthly)2.83
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

    Issuer: CureVac / Key word(s): Quarterly / Interim Statement16.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 St

  • EQS Group

    CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

    Issuer: CureVac / Key word(s): Study11.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Presents Preliminary Data from Phase 1 Study Expansionof Oncology Candidate CV8102 Data confirm CV8102’s safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, Germany/ Boston, USA – November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global bio

  • EQS Group

    CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

    Issuer: CureVac / Key word(s): Quarterly / Interim Statement10.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report finan